Results 171 to 180 of about 213,141 (301)

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Targeting the Leukemia Inhibitory Factor/Leukemia Inhibitory Factor Receptor Axis Reduces the Growth of Inflammatory Breast Cancer by Promoting Ferroptosis. [PDF]

Cancers (Basel)
Romo B, Fuentes Z, Randolph L, Mahajan M, Aller EJ, Ebrahimi B, Santhamma B, Pratap UP, Subbarayalu P, Nagandla H, Thomas C, Nair HB, Vadlamudi RK, Viswanadhapalli S.   +13 more
europepmc   +1 more source

Depletion of the RNA‐Editing Enzyme ADAR1 Invigorates the Antitumor Immunity of NK Cells

Advanced Science, EarlyView.
ADAR1 is upregulated in NK cells from melanoma patients, impairing their function. Its loss enhances NK cell tumor infiltration and cytotoxicity in vitro and in vivo. Mechanistically, ADAR1 deficiency destabilizes CD38 mRNA to reduce its expression, thereby increasing NK cell mobility and killing, which nominates it as a therapeutic target for NK cell ...
Shuhan Chen, Di Lu, Rukang Liang, Weikeng Tan, Erming Zhao, Sihuang Wu, Xintong Li, Yulong Song, Miaojian Wan, Xiaoyuan Xie, Qi Zhang, Qiuli Liu   +11 more
wiley   +1 more source

Immunohistochemical expression pattern of leukemia inhibitory factor and its receptor may mark a tipping point in the progression of oral cancer. [PDF]

Sci Rep
Yakin M, Seo B, Hussaini HM, Rich AM.
europepmc   +1 more source

Production of biologically active recombinant buffalo leukemia inhibitory factor (BuLIF) in Escherichia Coli. [PDF]

J Genet Eng Biotechnol, 2022
Jamwal S, Ansari S, Malakar D, Kaushik JK, Kumar S, Mohanty AK.   +5 more
europepmc   +1 more source

BCR::ABL1‐Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B‐ALL Cells to Enhancer‐Targeting Drugs

Advanced Science, EarlyView.
Ng et al. show that the BCR::ABL1 kinase that drives the lymphoid leukemia Ph+B‐ALL modulates enhancer function by coopting signaling‐inducible transcription factors such as MYC, STAT5, and ETV5. BCR::ABL1 thereby promotes the transcriptional program driving and defining this leukemia and renders Ph+B‐ALL cells hypersensitive to enhancer‐inhibiting ...
Han Leng Ng, Trudy Lee Glaser, Jintao Zhu, Mark E. Robinson, Kadriye N. Cosgun, Valeriya Malysheva, Ozgen Deniz, Nicholas T. Crump, Kaiyue Helian, Andrew J. Innes, Richard Burt, Li Sun, George John, Haibin Zhou, Atsunori Kaneshige, Longchuan Bai, Shaomeng Wang, Mikhail Spivakov, Markus Müschen, Niklas Feldhahn   +19 more
wiley   +1 more source

Mesenchymal stem/stromal cells overexpressing leukemia inhibitory factor (LIF) promote arteriogenesis and functional recovery in a mouse model of critical hindlimb ischemia. [PDF]

Stem Cell Res Ther
Santos GC, Azevedo CM, Ribeiro TO, Costa BDS, Santos IP, Nascimento MO, Dias RB, Silva DN, Mendez-Otero R, Fortuna V, Soares MBP.   +10 more
europepmc   +1 more source

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

Advanced Science, EarlyView.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang, Pan Lai, Mingjia Li, Yujie Wen, Mengzhou Cao, Yu Xiao, Zhuojing Chen, Jingru Sun, Yang Wang   +8 more
wiley   +1 more source

Exploring Boswellia serrata Triterpenes: A New Frontier in Leukemia Inhibitory Factor Receptor Modulation. [PDF]

ACS Omega
Finamore C, Festa C, Cammarota M, Spinelli L, Morretta E, Cassiano C, Monti MC, Marchianò S, Massa C, Moraca F, Lupia A, Catalanotti B, Fiorucci S, Zampella A, De Marino S.   +14 more
europepmc   +1 more source

Hypofractionated Radiotherapy Induces ISG15+MHC‐I+ Neutrophils to Augment Anti‐Tumor Immunity and Prime Immune Checkpoint Blockade Responses in Rectal Cancer

Advanced Science, EarlyView.
ABSTRACT Our previous clinical trials had demonstrated that neoadjuvant hypofractionated radiotherapy (HFRT) combined with immunotherapy yields promising clinical outcomes in locally advanced rectal cancer (LARC). However, this combined modality benefits only a subset of patients, highlighting the need to uncover the mechanisms underlying how ...
Lichao Liu, Haihong Wang, Mingjie Li, Qian Xu, Linlin Zheng, Chaoqun Han, Zhenwei Zou, Jinghua Ren, Xiaorong Dong, Peng Zhang, Kaixiong Tao, Zhenyu Lin, Tao Zhang   +12 more
wiley   +1 more source